Medicare Enrolled
Dr. Khaled Tawansy, M.D.
Ophthalmology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tawansy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tawansy?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tawansy
Dr. Khaled Tawansy is an ophthalmology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Tawansy performed 7,799 Medicare services across 2,357 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tawansy received a total of $10,688 from 47 pharmaceutical and/or device companies across 504 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tawansy is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in CA
$10,688 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,799
Medicare services
Top 12% in CA for ophthalmology
2,357
Unique beneficiaries
$360
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~410 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Aflibercept eye injection (Eylea) | 3,340 | $694 | $1,237 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
1,082 | $129 | $1,182 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
1,075 | $32 | $100 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
903 | $96 | $225 |
| Extended eye exam with retinal drawing A detailed examination of the back of the eye that includes creating a drawing of the retina. |
294 | $20 | $55 |
| Compounded drug, not otherwise classified A medication prepared specifically for an individual patient by a pharmacist or physician, tailored to meet unique needs that cannot be fulfilled by commercially available products. |
282 | $72 | $100 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
194 | $70 | $160 |
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
105 | $35 | $161 |
| Cataract surgery with lens implant Surgical removal of the clouded natural lens of the eye and replacement with an artificial prosthetic lens to restore vision. |
90 | $301 | $2,500 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
58 | $119 | $338 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
47 | $1 | $20 |
| Vitreous removal between lens and retina This procedure involves the removal of the vitreous fluid located between the lens and the retina of the eye. |
38 | $671 | $3,079 |
| Extended exam of back of eye with optic nerve drawing A detailed examination of the posterior section of the eye, including the optic nerve, with documentation through drawing. |
34 | $12 | $76 |
| Retinal membrane and internal limiting membrane removal A surgical procedure to remove a membrane from the retina along with the internal limiting membrane of the retina. |
32 | $944 | $3,000 |
| Removal of retinal membrane A surgical procedure to remove a membrane from the surface of the retina. |
27 | $811 | $3,000 |
| Aspiration of eye fluid between lens and retina A procedure to remove fluid located between the lens and the retina of the eye. |
22 | $572 | $1,284 |
| Aspiration of lens material by fragmenting and aspiration | 20 | $340 | $2,000 |
| Laser removal of recurring cataract A laser procedure to remove a recurring cataract within the lens capsule. |
18 | $285 | $750 |
| Laser vitreolysis A laser procedure used to destroy fluid in the vitreous of the eye, located between the lens and the retina. |
18 | $779 | $3,000 |
| Complex detached retina repair with eye fluid drainage A surgical procedure to repair a detached retina and drain fluid located between the lens and the retina. |
18 | $1,129 | $3,000 |
| Comprehensive eye exam, new patient A comprehensive examination of the visual system performed for a new patient. |
18 | $89 | $300 |
| Complete ultrasound of brain blood flow An ultrasound test that evaluates blood flow within the brain's blood vessels. It uses sound waves to create images of the vessels and assess circulation. |
18 | $230 | $550 |
| Ultrasound of brain blood flow following medication An ultrasound test used to assess blood flow within the brain after a medication has been administered. |
18 | $225 | $600 |
| Ultrasound of brain blood flow An ultrasound test used to examine blood flow within the brain to check for blood clots. |
18 | $99 | $600 |
| Optic nerve imaging (OCT scan) Imaging of the optic nerve. |
16 | $31 | $131 |
| Injection into eye membrane A procedure involving the injection of a drug or substance into the membrane that covers the eyeball. |
14 | $25 | $219 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.2% high complexity
73.5% medium
25.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,688
Total received (2018-2024)
Avg $1,527/year across 7 years
Top 14% in CA for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
504
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,599 (89.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$850 (8.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$239 (2.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,817
2023
$1,774
2022
$2,059
2021
$1,143
2020
$754
2019
$1,118
2018
$2,023
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Biogen, Inc.
$349
Mallinckrodt Hospital Products Inc.
$340
ABBVIE INC.
$290
Oyster Point Pharma, Inc.
$178
SUN PHARMACEUTICAL INDUSTRIES INC.
$139
Bausch & Lomb Americas Inc.
$91
Astellas Pharma US Inc
$71
Dompe US, Inc.
$69
Alcon Vision LLC
$67
ANI Pharmaceuticals, Inc.
$62
Johnson & Johnson Surgical Vision, Inc.
$61
Amgen Inc.
$45
Tarsus Pharmaceuticals, Inc.
$29
Harrow Eye, LLC
$26
Top 3 companies account for 53.9% of 2024 payments
All-time payments by company (2018-2024) ›
Mallinckrodt Hospital Products Inc.
$1,370
Novartis Pharmaceuticals Corporation
$1,310
Sun Pharmaceutical Industries Inc.
$1,060
Dutch Ophthalmic Research Center (International) B.V.
$850
Johnson & Johnson Surgical Vision, Inc.
$645
SUN PHARMACEUTICAL INDUSTRIES INC.
$592
Allergan, Inc.
$515
Allergan Inc.
$368
Biogen, Inc.
$349
ABBVIE INC.
$290
Dompe US, Inc.
$286
ANI Pharmaceuticals, Inc.
$273
Travere Therapeutics, Inc.
$228
Horizon Therapeutics plc
$208
Glaukos Corporation
$204
Alcon Vision LLC
$194
Bausch & Lomb, a division of Bausch Health US, LLC
$185
Oyster Point Pharma, Inc.
$178
Mallinckrodt Enterprises LLC
$144
Carl Zeiss Meditec USA, Inc.
$133
Aerie Pharmaceuticals, Inc.
$131
Thea Pharma Inc.
$128
Eyevance Pharmaceuticals LLC
$110
Bausch & Lomb Americas Inc.
$109
Mallinckrodt LLC
$102
Dutch Ophthalmic, USA
$91
Astellas Pharma US Inc
$71
Shire North American Group Inc
$49
Amgen Inc.
$45
EyePoint Pharmaceuticals US, Inc.
$43
Exeltis, USA Inc.
$36
Kala Pharmaceuticals, Inc.
$35
EYEVANCE PHARMACEUTICALS LLC
$34
Alimera Sciences, Inc.
$34
Retrophin, Inc.
$31
AbbVie Inc.
$30
Tarsus Pharmaceuticals, Inc.
$29
Harrow Eye, LLC
$26
BIOTISSUE HOLDINGS, INC.
$24
Spark Therapeutics, Inc.
$24
Genentech USA, Inc.
$21
Sight Sciences, Inc.
$21
Vanda Pharmaceuticals Inc.
$20
Carl Zeiss Meditec, Inc.
$17
TearLab Corp
$16
GENZYME CORPORATION
$15
OPTOS, INC.
$13
Top 3 companies account for 35.0% of all-time payments
Associated products mentioned in payments ›
(820) Cholbam · ACTHAR · ALPHAGAN P · BROMSITE · BYOOVIZ · BromSite (bromfenac ophthalmic solution) 0.075% · CEQUA · CIRRUS HD-OCT · COMBIGAN · Cequa · Cholbam · Clareon · DEXYCU · DUREZOL · DURYSTA · EVA · EVA Ophthalmic Surgical System · Flarex · HETLIOZ · INVELTYS · ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM · Iluvien · Izervay · LOTEMAX · LOTEMAX GEL · LUMIGAN · LUXTURNA · None Specified · OMNI(R) SURGICAL SYSTEM (US) · OXERVATE · OZURDEX · P200DTx · PROKERA · PROLENSA · PURIFIED CORTROPHIN GEL · RESTASIS MULTIDOSE · Rhopressa · Rocklatan · SIMBRINZA · Simbrinza · TECNIS IOL · TEPEZZA · TRAVATAN Z · TYRVAYA · TearLab Osmolarity System · TearScience Lipiflow System · Tecnis IOL · Tecnis Multifocal Family of 1-piece IOLS · Tecnis Simplicity · TobraDex ST · Tobradex ST · VABYSMO · VEVYE · VUITY · VYZULTA · XDEMVY · XELPROS · XEN · XEN GLAUCOMA TREATMENT SYSTEM · XIIDRA · XIPERE · combined machine · iStent inject Trabecular Micro-Bypass Stent System · rocklatan
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Ophthalmologists within 10 mi
775
Per 100K population
7.9
County median income
$87,760
Nearest hospital
GLENDALE ADVENTIST MEDICAL CENTER
1.6 mi
1.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tawansy is a mixed practice specialist, with above-average Medicare volume (top 12% in CA), with low-engagement industry engagement in the top 14% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tawansy experienced with aflibercept eye injection (eylea)?
Based on Medicare claims data, Dr. Tawansy performed 3,340 aflibercept eye injection (eylea) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tawansy receive payments from pharmaceutical companies?
Yes. Dr. Tawansy received a total of $10,688 from 47 companies across 504 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tawansy's costs compare to other ophthalmologists in Los Angeles?
Dr. Tawansy's average Medicare payment per service is $360. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tawansy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Ophthalmologists in Los Angeles
Browse ophthalmologists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Ophthalmologists in CA
Ophthalmologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Ophthalmologists in CA
Which CA ophthalmologists receive the most from drug and device companies.
By company
Mallinckrodt Hospital Products Inc. Payments to Doctors
See all physicians who received payments from Mallinckrodt Hospital Products Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Sun Pharmaceutical Industries Inc. Payments to Doctors
See all physicians who received payments from Sun Pharmaceutical Industries Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology